ABBV AbbVie Inc.
Price Chart
Executive Summary
AbbVie updated its 2026 adjusted diluted EPS guidance to $13.96–$14.16, incorporating a $0.41 per share impact from Q1 2026 acquired IPR&D and milestones expense. This follows the company's prior full-year guidance of $14.37–$14.57, which excluded such expenses.
Actionable Insight
Monitor upcoming Q1 2026 earnings for confirmation of the $744 million IPR&D expense and final EPS results; the updated guidance range implies slightly lower profitability expectations for the year.
Key Facts
- AbbVie issued updated 2026 full-year adjusted diluted EPS guidance of $13.96–$14.16, down from prior range of $14.37–$14.57
- The reduction reflects a $0.41 per share impact from acquired IPR&D and milestones expense incurred in Q1 2026
- The company does not forecast future IPR&D or milestones expenses due to uncertainty in timing and occurrence
- This filing provides preliminary estimates; final results are subject to closing procedures
Financial Impact
Full-year adjusted EPS guidance reduced by $0.41 to $13.96–$14.16, reflecting $744 million in Q1 2026 acquired IPR&D and milestones expense
Risk Factors
- Future IPR&D and milestones expenses remain uncertain and could further impact earnings
- Preliminary estimates are subject to change upon final financial closing
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000011 |
| Document: abbv-20260331nonxgaapxex991.htm | 0001551152-26-000011 |
| Document: 0001551152-26-000011-index-headers.html | 0001551152-26-000011 |
| Document: 0001551152-26-000011-index.html | 0001551152-26-000011 |
| Document: 0001551152-26-000011.txt | 0001551152-26-000011 |
| 8-K Data (Synthetic) | 0001551152-26-000011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 31, 2026
9d ago
|
ANALYST-UPGRADE
| $221.54 $220.69 | ▼ −0.39% | ▲ +1.96% | $225.42 (+1.75%) |
|
May 21, 2026
19d ago
|
ANALYST-UPGRADE
| $205.12 $197.69 | ▼ −3.62% | ▼ −4.71% | $225.42 (+9.90%) |
|
May 18, 2026
23d ago
|
Court Ruling
| $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $225.42 (+7.65%) |
|
May 1, 2026
5w ago
|
ANALYST-UPGRADE
| $221.54 $220.69 | ▼ −0.39% | ▲ +1.96% | $225.42 (+1.75%) |
|
Apr 29, 2026
5w ago
|
8-K
| $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $225.42 (+10.56%) |
|
Apr 21, 2026
7w ago
|
ANALYST-UPGRADE
| $205.12 $197.69 | ▼ −3.62% | ▼ −4.71% | $225.42 (+9.90%) |
|
Apr 3, 2026
9w ago
|
8-K
| $204.99 $204.77 | ▼ −0.11% | ▼ −4.24% | $225.42 (+9.97%) |
|
Mar 23, 2026
11w ago
|
DEFA14A
| $203.51 $215.70 | ▲ +5.99% | ▲ +6.41% | $225.42 (+10.77%) |
|
Mar 2, 2026
14w ago
|
Insider Cluster
| $232.33 $225.58 | ▲ +2.91% | ▲ +1.70% | $225.42 (+2.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access